The public registers hold a second record for Siegfried Grafton. The fuller profile, with 94 active US DMFs and 40 valid CEPs, is at Siegfried. Figures on this page cover only this record.
Siegfried Grafton is an API manufacturer based in United States. It holds 9 active US drug master files and 3 valid CEPs across a filed portfolio of 9 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 14 August 2024 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Grafton, United States | Not on file |
| Grafton, United States | 3001655239 |
| Molecule | Regulators | Docs |
|---|---|---|
| Fentanyl | EDQM, US FDA | 3 |
| Brimonidine | EDQM, US FDA | 2 |
| Benzatropine | US FDA | 1 |
| Flavin Mononucleotide | US FDA | 1 |
| Fluoxymesterone | US FDA | 1 |
| Methylnaltrexone | US FDA | 1 |
| Nepafenac | US FDA | 1 |
| Oxandrolone | US FDA | 1 |
| Travoprost | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Ask Fred what the record holds on Siegfried Grafton, including filings and inspection history.
Chat with Fred, your AI analystRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.